Johnson & Johnson to Invest Over $55 Billion in US Manufacturing Facilities
The investment, which is a 25% increase from previous years, will support three new advanced manufacturing facilities, expansions at existing sites, and R&D efforts.
Image Credit: Adobe Stock Images/Andrii Zastrozhnov
Johnson & Johnson (J&J) announced plans to invest over $55 billion in manufacturing facilities in the United States over the next four years, representing a 25% increase from previous investments. According to the company, the investment will support three new manufacturing facilities, the expansion of existing sites, and significant R&D efforts in oncology, neuroscience, immunology, cardiovascular disease, and robotic surgery.1
“Today’s announcements accelerate our nearly 140-year legacy as an American innovation engine tackling the world’s toughest healthcare challenges,” said Joaquin Duato, chairman, CEO, J&J, in a press release. “Our increased US investment begins with the ground-breaking of a high-tech facility in North Carolina that will not only add US-based jobs but manufacture cutting edge medicines to treat patients in America and around the world.”
A key component of this initiative is the construction of a new 500,000-square-foot biologics manufacturing facility in Wilson, North Carolina. According to J&J, the new facility is expected to create around 5,000 jobs during the construction period and is projected to contribute $3 billion to North Carolina’s economy within its first decade of operations.1
“We are pleased to make this significant investment in our manufacturing network in the United States. This state-of-the-art biologic facility in North Carolina will help Johnson & Johnson to accelerate the delivery of our portfolio and pipeline of transformational medicines for patients,” said Jennifer Taubert, EVP, worldwide chairman, innovative medicine, J&J, in a press release. “This $2 billion investment will bring more than 5,000 high-wage manufacturing and construction jobs to North Carolina and the partnerships we are forging in the community will support local educational initiatives to develop the workforce of the future.”
Once completed, the facility will add approximately 500 positions, including process technicians, laboratory analysts, engineers, and microbiologists. J&J stated that this could potentially lead to a payroll of approximately $45 million.1,2
“Johnson & Johnson is a recognized industry leader in pharmaceutical research, development and manufacturing, and we are proud to be part of the Wilson community,” said Dapo Ajayi, VP, innovative medicine supply chain, J&J, in the press release. “This is a major investment and an exciting time as we start construction on this advanced manufacturing facility, using the latest technology and building a highly skilled workforce to deliver on our promise to patients.”
As part of the investment, J&J also announced its intentions to support education and workforce development in Wilson. This includes continued work with the Smithsonian Science Education Center to bring science, technology, engineering, and mathematics programming to schools in the area. Additionally, J&J will work to implement the BioWork certificate program in Wilson County. The goal of the program is to provide students with a path toward future employment with the company or other life science organizations.2
“Wilson is an important life sciences hub, and I am excited to welcome Johnson & Johnson as it expands its manufacturing footprint in our state,” said Josh Stein, Governor of North Carolina, in the press release. “I look forward to seeing the impact this investment will have on medical innovation and North Carolina’s workforce.”
References
1. Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years. Johnson & Johnson. March 21, 2025. Accessed March 21, 2025. https://www.jnj.com/media-center/press-releases/johnson-johnson-increases-u-s-investment-to-more-than-55-billion-over-the-next-four-years
2. Johnson & Johnson to break ground on new state-of-the-art biologics facility in North Carolina to deliver market-leading portfolio of transformational therapies. Johnson & Johnson. March 21, 2025. Accessed March 21, 2025. https://www.jnj.com/media-center/press-releases/johnson-johnson-to-break-ground-on-new-state-of-the-art-biologics-facility-in-north-carolina-to-deliver-market-leading-portfolio-of-transformational-therapies
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
